We use cookies to ensure our site functions properly and to store limited information about your usage. You may give or withdraw consent at any time. To find out more, read our privacy policy and cookie policy.
Manage Cookies
A cookie is information stored on your computer by a website you visit. Cookies often store your settings for a website, such as your preferred language or location. This allows the site to present you with information customized to fit your needs. As per the GDPR law, companies need to get your explicit approval to collect your data. Some of these cookies are ‘strictly necessary’ to provide the basic functions of the website and can not be turned off, while others if present, have the option of being turned off. Learn more about our Privacy and Cookie policies. These can be managed also from our cookie policy page.
Strictly necessary cookies(always on):
Necessary for enabling core functionality. The website cannot function properly without these cookies. This cannot be turned off. e.g. Sign in, Language
Analytics cookies:
Analytical cookies help us to analyse user behaviour, mainly to see if the users are able to find and act on things that they are looking for. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. Tools used: Google Analytics
Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron
Share Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron on FacebookShare Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron on TwitterShare Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron on LinkedinEmail Consultation on proposed commitments in respect of Vifor Pharma’s supply of intravenous iron link
The Competition and Markets Authority's (CMA) purpose is to help people, businesses and the UK economy by protecting competition and tackling unfair behaviour.
About this consultation
The CMA is consulting on commitments offered by Vifor Pharma in relation to the CMA’s investigation into Vifor Pharma’s conduct in the market for the supply of high-dose intravenous iron, under the Chapter II prohibition of the Competition Act 1998. The CMA’s investigation relates to concerns that Vifor Pharma made potentially misleading claims about a competitor’s intravenous iron treatment, Monofer, supplied by Pharmacosmos, as compared to Vifor Pharma’s own product, Ferinject.
To address the competition concerns the CMA identified during the course of its investigation, Vifor Pharma has offered commitments to:
make an ex-gratia payment of £23 million to the NHS
correct any potentially misleading communications disseminated by Vifor Pharma regarding the safety of Monofer and Ferinject, via a multi-channel communications campaign to healthcare professionals
introduce several compliance measures to prevent the future dissemination of potentially misleading communications regarding the safety of Monofer and Ferinject to healthcare professionals
This consultation closed at 5pm on 17 January 2025.
The CMA does not intend to publish any responses, however, the information contained in the responses may be used or summarised on an anonymous basis. If your response contains any information that you regard as sensitive and that you would not wish to be published, please identify the information and explain why you regard it as sensitive.
Your personal data
Any personal data you provide to us through CMA Connect (such as your name and contact details) will be handled in accordance with our obligations under the UK General Data Protection Regulation and the Data Protection Act 2018.
Our personal information charter(External link) set out the standards you can expect from us when we collect, use or share personal data and provides details of your rights in relation to that personal data and how to contact us.
The Competition and Markets Authority's (CMA) purpose is to help people, businesses and the UK economy by protecting competition and tackling unfair behaviour.
About this consultation
The CMA is consulting on commitments offered by Vifor Pharma in relation to the CMA’s investigation into Vifor Pharma’s conduct in the market for the supply of high-dose intravenous iron, under the Chapter II prohibition of the Competition Act 1998. The CMA’s investigation relates to concerns that Vifor Pharma made potentially misleading claims about a competitor’s intravenous iron treatment, Monofer, supplied by Pharmacosmos, as compared to Vifor Pharma’s own product, Ferinject.
To address the competition concerns the CMA identified during the course of its investigation, Vifor Pharma has offered commitments to:
make an ex-gratia payment of £23 million to the NHS
correct any potentially misleading communications disseminated by Vifor Pharma regarding the safety of Monofer and Ferinject, via a multi-channel communications campaign to healthcare professionals
introduce several compliance measures to prevent the future dissemination of potentially misleading communications regarding the safety of Monofer and Ferinject to healthcare professionals
This consultation closed at 5pm on 17 January 2025.
The CMA does not intend to publish any responses, however, the information contained in the responses may be used or summarised on an anonymous basis. If your response contains any information that you regard as sensitive and that you would not wish to be published, please identify the information and explain why you regard it as sensitive.
Your personal data
Any personal data you provide to us through CMA Connect (such as your name and contact details) will be handled in accordance with our obligations under the UK General Data Protection Regulation and the Data Protection Act 2018.
Our personal information charter(External link) set out the standards you can expect from us when we collect, use or share personal data and provides details of your rights in relation to that personal data and how to contact us.
